At a meeting in Oslo in August, Incentives for Global Health, a nonprofit organization directed by Aidan Hollis, professor of economics at the University of Calgary, and Thomas Pogge, professor of philosophy and international affairs at Yale, launched a radical new proposal to change the incentives under which corporations are rewarded for developing new medicines. They suggest that governments contribute to a Health Impact Fund that would pay pharmaceutical companies in proportion to the extent to which their products reduce the global burden of disease.
该基金不会取代现有的专利法，但是会提供一项变通。制药公司可以继续和现在一样为它们的产品注册专利并进行销售，而变通的是，他们可以向健康影响基金注册另一种新药名，基金再按照此药的生产成本定一个比较低的价格。